Shares of Clene Inc. fell 14.7% on Tuesday after the biopharmaceutical company announced an underwritten registered direct offering of 1,000,000 shares of its common stock priced at $7.00 per share to a single institutional investor.
The company said the sale is expected to produce approximately $7 million in gross proceeds before underwriting discounts, commissions, and other estimated offering expenses. The transaction is scheduled to close on or about May 6, 2026, subject to customary closing conditions.
Clene indicated that the net proceeds from the offering, together with its existing cash reserves, will be used primarily for general corporate purposes. The company also enumerated specific uses tied to its lead therapeutic candidate, CNM-Au8: supporting the preparation and filing of a New Drug Application, maintaining and enabling continued access to CNM-Au8 in ongoing expanded access protocols, and supporting activities related to a potential confirmatory Phase 3 clinical trial.
Additional stated uses for the funds include manufacturing expansion, resources for potential future commercialization initiatives, and early-stage research and development projects. Clene focuses its development efforts on treatments for neurodegenerative diseases, naming amyotrophic lateral sclerosis and multiple sclerosis as areas of interest.
Canaccord Genuity LLC is acting as the sole bookrunner for the offering.
The announced offering and the expected proceeds follow standard capital-raising practice for clinical-stage biopharmaceutical companies that are financing regulatory and trial activities while maintaining ongoing operations. The company has not altered the projected closing date or the pricing disclosed in the offering announcement.
Key points
- Clene disclosed an underwritten registered direct offering of 1,000,000 common shares at $7.00 per share, expected to yield about $7 million in gross proceeds.
- The net proceeds, together with existing cash, are earmarked primarily for general corporate purposes and to support the regulatory and clinical pathway for CNM-Au8, including a New Drug Application and a possible Phase 3 trial.
- Sectors impacted include biotechnology and healthcare, and the offering reverberated in capital markets as evidenced by the stock's 14.7% decline on the announcement day.
Risks and uncertainties
- The offering is subject to customary closing conditions, creating uncertainty as to whether the transaction will close as scheduled.
- The issuance of 1,000,000 new shares will affect existing shareholders through dilution once the offering is completed.
- Clene intends to use proceeds to advance regulatory filings and clinical development, activities that inherently carry execution and regulatory uncertainties tied to the biotech and healthcare sectors.
Canaccord Genuity LLC is serving as the sole bookrunner for the offering. The company has provided the pricing, timing, and intended use of proceeds as part of its disclosure around the registered direct offering.